LBX2 and ovarian carcinoma: We also propose that high expression levels of LBX2‐AS1 might lead to the increased resistance to chemotherapy or radiotherapy of ovarian cancer cells, considering that Reimer et al have reported the significant association between the high expression levels of E2F2 and increased platinum drug resistance in ovarian cancer patients.31